S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"White Gold" is the New Oil (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Magna International is Your Auto and EV One-Stop Shop Stock
"White Gold" is the New Oil (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"White Gold" is the New Oil (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Magna International is Your Auto and EV One-Stop Shop Stock
"White Gold" is the New Oil (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"White Gold" is the New Oil (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Magna International is Your Auto and EV One-Stop Shop Stock
"White Gold" is the New Oil (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
"White Gold" is the New Oil (Ad)
Russia's lower house of parliament endorses treaties for 4 regions of Ukraine to join Russia
Brazil holds historic election with Lula against Bolsonaro
"White Gold" is the New Oil (Ad)
US shift away from coal hits tribal community in New Mexico
Magna International is Your Auto and EV One-Stop Shop Stock
"White Gold" is the New Oil (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
NASDAQ:AGIO

Agios Pharmaceuticals - AGIO Stock Forecast, Price & News

$28.28
-0.29 (-1.02%)
(As of 09/30/2022 09:00 PM ET)
Add
Compare
Today's Range
$28.19
$29.54
50-Day Range
$19.51
$34.14
52-Week Range
$16.75
$50.98
Volume
639,600 shs
Average Volume
671,322 shs
Market Capitalization
$1.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.14

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
80.8% Upside
$51.14 Price Target
Short Interest
Bearish
10.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.09
Upright™ Environmental Score
News Sentiment
1.22mentions of Agios Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.89) to ($6.35) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

691st out of 1,095 stocks

Pharmaceutical Preparations Industry

335th out of 547 stocks

AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down to $29.80
Agios Appoints Cecilia Jones as Chief Financial Officer
Agios Pharmaceuticals Gets CHMP Backing for Pyrukynd
A Technical Strategy to 'Buy' Agios Pharmaceuticals
Agios to Participate in September Investor Conferences
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings
8/04/2022
Today
10/03/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.14
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+80.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$1.60 billion
Pretax Margin
-5,759.63%

Debt

Sales & Book Value

Annual Sales
$203.20 million
Book Value
$23.79 per share

Miscellaneous

Free Float
52,362,000
Market Cap
$1.55 billion
Optionable
Optionable
Beta
1.18

Key Executives

  • Mr. Jonathan Biller J.D.Mr. Jonathan Biller J.D. (Age 57)
    CFO & Head of Corp. Affairs
    Comp: $804.18k
  • Dr. Bruce Car Ph.D. (Age 60)
    Consultant
    Comp: $776.12k
  • Dr. Sarah Gheuens M.D. (Age 42)
    Ph.D., Chief Medical Officer and Head of R&D
    Comp: $1.57M
  • Ms. Richa Poddar (Age 40)
    Chief Commercial Officer
    Comp: $624.08k
  • Mr. Brian M. Goff M.B.A. (Age 53)
    CEO & Director
  • Dr. Lewis Clayton Cantley Ph.D. (Age 73)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Tak Wah Mak D.Sc. (Age 76)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 69)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 66)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. T. J. Washburn Jr. (Age 41)
    Principal Accounting Officer













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2022?

7 Wall Street analysts have issued 12 month price objectives for Agios Pharmaceuticals' stock. Their AGIO share price forecasts range from $16.00 to $96.00. On average, they expect the company's stock price to reach $51.14 in the next twelve months. This suggests a possible upside of 80.8% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2022?

Agios Pharmaceuticals' stock was trading at $32.87 at the beginning of 2022. Since then, AGIO stock has decreased by 14.0% and is now trading at $28.28.
View the best growth stocks for 2022 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.10. The biopharmaceutical company had revenue of $5.58 million for the quarter, compared to analyst estimates of $2.86 million. Agios Pharmaceuticals's quarterly revenue was up 5482.0% on a year-over-year basis. During the same period last year, the firm posted ($1.36) EPS.

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $28.28.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.55 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.72) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 390 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.